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There is an urgent need to develop and validate a series of biomarkers, which accurately measure and inform on how the human gut microbiota can
affect human health. The human gut hosts a complex community of micro-organisms, with unique features in each individual. The functional role
of this gut microbiota in health and disease is increasingly evident, but poorly understood. Comprehension of this ecosystem implies a significant
challenge in the elucidation of interactions between all of its components, but promises a paradigm shift in preventive nutrition and medicine.
‘Omics’ technologies for the first time offer tools of sufficient subtlety to tackle this challenge. However, these techniques must be allied with
traditional skills of the microbial physiologist, which are in danger of being lost. Targeting these efforts at the identification of biomarkers associ-
ated with gut health will require access to a ‘biobank’ from a pan-European or worldwide observation study, which would include samples taken
with appropriate frequency from healthy individuals of different ages. This offers a pragmatic opportunity for a unique food and
pharmaceutical industry collaboration.
Intestinal microbiota: Predictive biomarkers: Gut health: Functional food
A workshop on the topic of Molecular biomarkers for
the healthy gut microbiota was held in Bucharest, Romania,
4–6 February 2008. The workshop was convened by the
Lactic Acid Bacteria Industrial Platform and was supported
financially by the EU funded Specific Support Action
GutImpact FP6-2003-517821. The aim of the present
workshop was (1) to establish the state of the art of validated
biomarkers and define expectations for ideal ones, (2) to give a
prospective view of current developments of high throughput
and molecular diagnostic methods and (3) to diminish the gap
between molecular methods, biomarkers identification
and strategies for product developments. The present report
summarises the discussion that took place at the workshop.
What is the gut microbiota?
It is widely acknowledged that microbes residing in the human
gut (the gut microbiota) are hugely significant in terms of
human health. Various estimates suggest that the microbiota
weighs about 1·5 kg and comprises approximately 95 % of
the total number of cells in the body(1). They are responsible
for degrading certain food components and endogenous
mucins, producing vitamins, preventing the colonisation or
proliferation of pathogens and producing essential digestive
and protective enzymes(2,3). As a result, they are thought to
improve lactose intolerance, carry anti-tumour properties,
neutralise certain toxins and reduce blood lipid levels(4).
However, consequences of their metabolic potential may be
the activation of substances with adverse health effects(5).
Gut microbes are both numerous and diverse. All three
domains of life, Archaea, Bacteria and Eukarya, are
represented. It is, however, the Bacteria that dominate
the ecosystem, and in contrast to Archaea and Eukarya,
they are present in everybody. Dominant bacteria that
are regularly detected in intestinal contents of healthy indivi-
duals predominantly belong to four phyla: Actinobacteria,
Bacteroidetes, Firmicutes and Verrucomicrobia (6). Many,
very different types of bacteria occur within each of these,
and over 420 species belonging to 117 different genera have
been cultivated and identified to date(6). When it is appreciated
that the huge majority (approximately 80 %) of the gut
microbiota cannot be cultured by conventional means, its
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true complexity comes into focus(7 – 9). Furthermore, in all
those subjects analysed so far, it transpires that more than
half of their gut microbes have not been found anywhere
else and a large proportion represents totally novel taxonomic
groups(9 – 12). It seems therefore inevitable that further analysis
of microbes from human gut samples will reveal novel phyla,
classes, orders, families, genera and species of microbes.
The gut microbiota of each individual and its stability over
time is thus a unique signature, as exquisite as the human
fingerprint(13,14). Extrapolation from available data suggests
that thousands if not tens of thousands of different microbial
species will eventually be assigned to it. In spite of the
large number of bacterial species, it is also becoming clear
that a significant proportion of dominant bacterial cells
belong to a little more than sixty core species highly con-
served between individuals(15).
Development and stability
The intestine of a normal fetus is sterile. During birth
and immediately afterwards, bacteria from the mother and
the surrounding environment colonise the infant gut.
Immediately after vaginal delivery, babies have bacterial
strains in the upper gastrointestinal tract derived from the
mothers’ colonic microbiota. Following birth, environmental,
oral and cutaneous bacteria are readily transferred from the
mother to the infant through suckling, kissing and
caressing(16). Within a few days, bacterial numbers reach
108–1010/g faeces(17). During the first week of life, these
bacteria create favourable conditions for the subsequent
bacterial succession of strict anaerobes mainly belonging to
the genera Bifidobacterium, Bacteroides, Clostridium and
Ruminococcus. Breast-fed babies become dominated by
bifidobacteria, possibly due to the presence of bifidobacterial
growth factors in breast milk(18). In contrast, the microbiota
of formula-fed babies is more diverse with high numbers of
Enterobacteriaceae, enterococci, bifidobacteria, Bacteroides
and clostridia. After the introduction of solid food and
weaning, the microbiota of formula-fed infants becomes
similar to that of breast-fed infants. By the second year of
life, the faecal microbiota resembles that of adults. Again,
there is a characteristic shift in the composition of the
intestinal microbiota upon ageing. In elderly persons,
bifidobacteria decrease or become subdominant, while lacto-
bacilli, enterococci, enterobacteria and clostridia increase(19).
This may be due to physiological and physico-chemical
alterations of the digestive environment with ageing. This in
turn may lead to increased risk of infection or degenerative
diseases such as cancer or disorders of liver function.
Relationship with human health
Intestinal health is a state of well-being of the bowel and
associated organs that is perceived at all stages of daily
life and activities including defecation and is not merely the
absence of intestinal discomfort.
Bacteria in the gut fulfil a host of useful functions
for human subjects, including digestion of energy-yielding
substrates stimulating cell growth; repression of harmful
micro-organisms; training the immune system to respond
only to pathogens; defence/protection against some diseases.
Hence, distortions in the composition of the bacterial
community or their expressed functionalities can be associated
with pathological conditions(20 – 22).
Digestion
Without gut microbiota, the human body could not utilise
some of the carbohydrates it consumes. Members of the
microbiota have enzymes absent from human cells thus
enabling them to break down certain non-digestible poly-
saccharides (e.g. dietary fibre)(23). They convert these into
SCFA that can be used by host cells, providing a major
source of useful energy and nutrients.
The SCFA are produced by a form of fermentation
called saccharolytic fermentation and include mainly acetic,
propionic and butyric acids(24). These can have important
physiological properties as follows: acetic acid is used by
muscle; propionic acid helps the liver to produce ATP and
may be used for gluconeogenesis; butyric acid provides
energy to gut epithelial cells. In addition, the SCFA help the
body to absorb nutrients such as Ca, Mg and Fe. Another
benefit of SCFA is that they increase growth of intestinal
epithelial cells and control their proliferation and diffe-
rentiation. Bacterial cells also modulate intestinal growth
by changing the expression of cell surface proteins such as
Na-dependent glucose transporters (Naþ-GLUT). In addition,
interaction between bacteria and gut epithelial cells may
prevent injury to the gut mucosa.
Repression of pathogenic microbial growth
Another important role of the microbiota is termed the ‘barrier
effect’(3). Growth of yeasts and harmful bacterial species such
as Clostridium difficile is limited by competition from the host
microbiota. The barrier effect protects human subjects from
both invading species and species normally present in the gut
at low numbers, whose growth is inhibited by the dominant
gut microbiota.
The normal dominant microbiota contains bacterial strains
that prevent the growth of pathogenic strains by competing
for nutrients and attachment sites to the epithelium of the
intestine. Symbiotic bacteria are favoured by this ecological
niche and are thus more successful in the competition. The
commensal bacteria may send chemical signals to the host
about the type and amount of nutrients they may use, and
the host responds accordingly(25), thereby possibly starving
out harmful bacteria. Commensal bacteria may also produce
bacteriocins, substances harmful to other microbes, which
may offer them an ecological advantage(26).
Immunity
The microbiota has a dynamic effect on the host’s gut and
systemic immune systems(27,28). Bacteria are thought to be
key in promoting early development of the gut’s mucosal
immune system and continue to play a role in its operation
later in life(28). Bacteria stimulate the lymphoid tissue
associated with the gut mucosa to produce antibodies to
both commensals and pathogens(29). The immune system
recognises and counteracts harmful bacteria, but leaves the
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helpful species alone, thanks to a tolerance mechanism most
likely developed in infancy.
Antibodies received from the mother via the placenta
or breastfeeding have the manifold role of imprinting
the specific B-cell repertoire, protecting the newborn and
shaping the microbiota(30). The first bacteria to colonise after
birth are able to affect the immune response, making it more
favourable to their own survival and less so to competing
species; thus, the first bacteria to colonise the gut are
important in determining the person’s lifelong gut microbiota
make-up.
Recent findings have shown that gut bacteria play a role
in the expression of toll-like receptors in the intestine,
molecules that help the host to repair damage due to injury.
Toll-like receptors cause parts of the immune system to
repair injury caused, for example, such as that by irradiation.
Bacteria can influence the phenomenon known as oral
tolerance, in which the immune system is less sensitive to
an antigen (including those produced by gut bacteria) once
it has been ingested. This tolerance, mediated in part by the
gastrointestinal immune system and in part by the liver, can
reduce an over-reactive immune response like those found in
allergies and autoimmune diseases(31).
Some species of gut microbiota, such as some of those in the
Bacteroides genus, are able to change their surface receptors
thereby evading immune responses(32). Bacteria with neutral
or harmful effects on the host may also have evolved these
types of strategies. The host immune system has also adapted
to this activity, preventing overgrowth of harmful species via
the release of specific antibodies that down regulate the
expression of epitopes involved in driving inflammatory
responses(33,34).
Preventing allergy
Bacteria are implicated in preventing allergies, an over-
reaction of the immune system to non-harmful antigens.
Studies on the gut microbiota of infants and young children
have shown that those who have allergies have different
gut microbiota from those without allergies(35), with
higher incidence of the harmful species C. difficile and
Staphylococcus aureus and lower prevalence of Bacteroides
and Bifidobacterium. One explanation is that since helpful
gut microbiota stimulate the immune system and ‘train’ it to
respond properly to antigens, a lack of these bacteria in
early life leads to an inadequately trained immune system,
which overreacts to harmless antigens(36).
Preventing inflammatory bowel disease
Another indication that commensal bacteria help to educate
the immune system is the epidemiology of inflammatory
bowel disease (IBD), such as Crohn’s disease. There is
some evidence, for example, that SCFA reduce symptoms of
IBD. In addition, some strains and species of bacteria can
prevent inflammation. The incidence and prevalence of IBD
are high in industrialised countries with a high standard
of living and low in less economically developed countries;
incidence has increased in developed countries throughout
the twentieth century. The disease is also linked to good
hygiene in youth; lack of breastfeeding; and consumption
of large amounts of sucrose and animal fat. Its incidence is
inversely linked with poor sanitation during the first years of
life and consumption of fruits, vegetables and unprocessed
foods. In addition, the use of antibiotics, which disrupt homo-
eostasis of the native gut microbiota along with harmful infec-
tious pathogens, especially during childhood, is associated
with IBD. On the other hand, using probiotics (bacteria con-
sumed as part of the diet that imparts health benefits aside
from just nutrition) can help to alleviate symptoms of certain
forms of IBD(37).
Factors affecting composition of the microbiota: the
development of biomarkers
The genotype of the host is thought to have the major influ-
ence on an individual’s microbiota. While the genome of an
adult is fixed, the composition of its microbiota may alter
with changes in lifestyle, diet and age. Molecular approaches
used to examine the individuality and stability of the micro-
biota over time and to detect shifts in its composition after
weaning could lead to the identification of biomarkers. In
medicine, a biomarker is defined as an indicator of a particular
disease state or a particular state of an organism. Specifically,
a biomarker is a characteristic that is objectively measured and
evaluated as an indicator of normal biological processes,
pathogenic processes or pharmacological responses to a
therapeutic intervention.
The scope for the identification of molecular biomarkers
has been greatly enhanced by ‘omics’ technologies. These
can unlock vast amounts of information stored in human
genes (genomics); their products i.e. expressed RNA (tran-
scriptomics) and translated proteins (proteomics); as well as
the many small molecules participating in metabolic processes
(metabolomics). These approaches are now being applied to
understand the role of the gut microbiome in human disease
using genomic analyses of microbial species from
‘humanised’ animal models and patient samples(38). There is
some evidence, for example, that aberrant compositional
development of the gut microbiota precedes weight gain/
obesity(21), offering new possibilities for preventive and
therapeutic applications in weight management(39).
Elsewhere, transcriptomic analysis has been used to under-
stand how interactions among specific gut microbial species
can affect host energy balance(40). For these analyses, a
humanised mouse model was used, mice were raised so that
the gut was free of microbes and then colonised with gut
microbes commonly found in human subjects(41). Two
microbial species in particular – Methanobrevibacter smithii
and Bacteroides thetaiotaomicron – were found to have a
cooperative relationship in digesting fibre as observed long
ago for the rumen microbiota. That leads to more efficient
intestinal nutrient absorption and energy storage as fat in a
simplified mouse model. Further research building on the
present work could lead to new ways to address both obesity
and undernourishment.
To identify molecular biomarkers for a healthy gut micro-
biota, it is appropriate to further advance the delineation
of criteria to define a normal homoeostatic microbiota and
further consider three sets of interactions: microbe–food,
microbe–host and microbe–microbe interactions.
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Microbe–food interactions
Fundamental questions underpinning the identification of
biomarkers indicative of these interactions include: how
does the microbiota respond to different dietary loads? What
is the long-term influence of the impact of food on early
colonisation? Is there imprinting from maternal feeding
during pregnancy? What is the influence of a high-fat diet
on the microbiota? How much energy is made available
to the host via SCFA produced by bacteria? How does
competition work between host and microbiota for various
food constituents (sugars and amino acids) and how significant
is it in terms of energy supply? Is it possible to identify key
molecules of bacterial origin in blood and/or urine?
Several observations indicate that this is a fertile area
for development. For example, it has been established that
maternal milk contains components that are ‘active’ towards
the microbiota. In addition, a high-fat diet is known to induce
a change in the microbiota and an increased production of
endotoxin(23). It is also possible to stimulate bifidobacteria
with fructo-oligosaccharides.
Catabolic pathways have been elucidated for major dietary
ingredients such as carbohydrates and proteins, and in some
cases, contributing micro-organisms have been identified
from in vitro studies of isolates. It is also clear that individual
differences in metabolic pathways exist and again, indicator
organisms can be identified. In either case, indicator meta-
bolites might be appropriate alternatives. A metabolic model
of food-compound degradation with predictive value using
environmental metabolomics and metagenomics data should
be the ultimate objective.
Microbe–host interactions
The focus of activity of microbiota–host interactions is the gut
barrier or mucosa(25,42 – 44). The normal colonisation of the
mammalian intestine with commensal microbes is thought to
drive the development of the host immune systems during
neonatal life and to maintain the physiologically steady
state of immune stimulation in the gut throughout life(27).
Therefore, biomarkers might be sought in mucus, epithelial
cells and other immunocompetent cells of the gut-associated
lymphoid tissues, and among anti-microbial peptides, secreted
antibodies and receptors of microbe-derived signals(29,45,46).
Questions that need to be answered include: should the
biomarkers be sought for locally in the gut or systemically?
Can a systemic biomarker represent a locally disregulated
response? Is it possible to identify systemic biomarkers that
can predict the onset of a disease, or is it possible that when
they reach the systemic level it is already too late and there
is overt disease?
On the microbe side, a ‘reverse science’ approach should
be adopted, using bioinformatics tools (existing or novel) in
order to identify genes that might code for a microbe’s surface
proteins. If a surface protein elicits an immune response of
interest, it will represent a potential biomarker.
Microbe–microbe interactions
Any given microbiota will contain about 1000 different
species of dominant bacteria(15). Given this complexity, it is
undoubted that bacterial communication and antagonism has
a dominant role in defining the microbial composition of
the gut. Consequently, it is vital that biomarkers that can
inform on or predict microbe–microbe interactions need to
be identified. These biomarkers will be developed based on
mechanisms by which bacteria communicate and affect each
others performance. These could include:
(1) Quorum-sensing where signals are produced by one
bacterium which are interpreted by its neighbour.
(2) Direct antagonism where a bacterium produces an anti-
microbial metabolite that kills susceptible microbes.
(3) Horizontal gene transfer mediated through conjugation,
transduction and transformation.
(4) Competitive exclusion whereby certain microbes pre-
dominate in particular niches.
(5) Tolerance and resistance to anti-microbials produced
by other gut microbes.
(6) Competition for nutrients.
(7) Oxidative species/redox balancing.
(8) Bacterial lysis, which would provide nutrients for growth
of opportunistic bacteria.
Initially, the most promising targets would be stable
biomarkers such as microbial signatures, metabolites or
nucleic acids. A metagenomic/metaproteomic profile is a
pattern of the presence or absence of particular genes or
proteins across a set of organisms. Such profiling of microbial
community structure at all levels of integrated microbiomics
would support the development of microbe–microbe
biomarkers, based on mechanisms of bacterial dominance,
persistence and dynamics.
A biobank for the development of preventive medicine
The identification of suitable biomarkers for disease is
hampered by the difficulty in defining precisely what the
healthy status of an individual means. Biomarkers should
first identify the health condition and assess how far an
individual deviates from this condition. Meaningful
investigations of any of these interactions and subsequent
development of biomarkers for preventive medicine require
access to large volumes of human sample material. The ideal
solution would be the establishment of a global ‘biobank’.
While this represents a major undertaking, the potential
returns make it attractive to both food and pharmaceutical
industries in collaboration with governments. Such an
initiative would analyse a population of healthy individuals
at the beginning that might develop disease over the years
of analysis. This would allow establishment and identification
of the health status of a population and identification of
biomarkers that are predictive of a particular disease. The
first step for such an exercise is to define operational
parameters. These include:
Population cohorts, for example: ages 0–21; 60–81
months; specific baby groups (normal v. caesarean delivery;
breastfed v. bottle fed).
Population size. This should be large enough to include
individuals that will develop a disease. For instance: if
9 % of children develop asthma, the population number
should be sufficiently high to reach statistical significance
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on the observed changed parameters in 9 % of the
population.
Nature of sampling procedures and material to be collected.
Standard protocols for sample collection would need to be
agreed. It is important to promote the idea that minimal inva-
sive techniques are acceptable and also that the associated
ethical issues need to be addressed. Rectal biopsy is, for
example, no more invasive than blood sampling at the physio-
logical level. Sampling of individuals should be linked to data
obtained from health/lifestyle questionnaires. Appropriate
material for collection includes faeces, blood, saliva and urine.
Nature of measurement. Microbiological level (i.e. taxa
from phylum to species and functional genes, proteins,
metabolites). Cytological level (i.e. genes, RNA, proteins
and metabolites).
Timing of sampling. At least one sampling per year, twice
for babies aged 0–3 months.
Approaches such as high-throughput sequencing and
tandem MS technologies are set to revolutionise measurement.
The volumes of data generated will necessitate a parallel
improvement in bioinformatics as more information will be
generated than can be processed in classical ways. Improved
tools need to be developed to integrate data and visualise it
in metabolic maps, in order to build testable hypothesis.
Alongside these cutting edge developments, it is important
not to neglect classical approaches. Expertise in bacterial
physiology (especially for anaerobic metabolism) has been
lost over time and tools must be developed to culture currently
non-culturable micro-organisms.
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